Potential and development of inhaled RNAi therapeutics for the treatment of pulmonary tuberculosis

Advanced Drug Delivery Reviews

Volumn 102, Issue , 2016, Pages 21-32

  Man, Dede K W ^a   Chow, Michael Y T ^a   Casettari, Luca ^b   Gonzalez Juarrero, Mercedes ^c   Lam, Jenny K W ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF URBINO   (Italy)

^c Veterinary Dentistry and Oral Surgery   (United States)

Author keywords

Host directed therapy; Inhalation; MicroRNA; Non viral vectors; Pulmonary delivery; RNAi delivery; Small interfering RNA; Tuberculosis

Indexed keywords

DRUG THERAPY; GENES; HEALTH RISKS;

HOST-DIRECTED THERAPY; INHALATION; MICRORNAS; NONVIRAL VECTORS; PULMONARY DELIVERY; RNAI DELIVERY; SMALL INTERFERING RNA; TUBERCULOSIS;

RNA;

RNA INDUCED SILENCING COMPLEX; SMALL INTERFERING RNA; TUBERCULOSTATIC AGENT;

CELL LEVEL; DRUG EFFICACY; DRUG TARGETING; EXTRACELLULAR SPACE; GENE SILENCING; HOST DIRECTED THERAPEUTICS; HUMAN; IMMUNOMODULATION; INHALATIONAL DRUG ADMINISTRATION; LUNG TUBERCULOSIS; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; REVIEW; RNAI THERAPEUTICS; GENETICS; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS;

ADMINISTRATION, INHALATION; ANTITUBERCULAR AGENTS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; RNAI THERAPEUTICS; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 84964681406     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2016.04.013     Document Type: Review

References (160)

1. Matteelli A., Roggi A., Carvalho A.C. Extensively drug-resistant tuberculosis: epidemiology and management. Clin. Epidemiol. 2014, 6:111-118.
2. WHO Definitions and Reporting Framework for Tuberculosis - 2013 Revision 2013.
3. Velayati A.A., Masjedi M.R., Farnia P., Tabarsi P., Ghanavi J., Ziazarifi A.H., Hoffner S.E. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest 2009, 136(2):420-425.
4. Blair H.A., Scott L.J. Delamanid: a review of its use in patients with multidrug-resistant tuberculosis. Drugs 2015, 75(1):91-100.
5. Brigden G., Hewison C., Varaine F. New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanid. Infect. Drug Resist. 2015, 8:367-378.
6. Esposito S., Bianchini S., Blasi F. Bedaquiline and delamanid in tuberculosis. Expert. Opin. Pharmacother. 2015, 16(15):2319-2330.
7. Lewis K. Platforms for antibiotic discovery. Nat. Rev. Drug Discov. 2013, 12(5):371-387.
8. Dyawanapelly S., Ghodke S.B., Vishwanathan R., Dandekar P., Jain R. RNA interference-based therapeutics: molecular platforms for infectious diseases. J. Biomed. Nanotechnol. 2014, 10(9):1998-2037.
9. Fujita Y., Takeshita F., Kuwano K., Ochiya T. RNAi therapeutic platforms for lung diseases. Pharmaceuticals 2013, 6(2):223-250.
10. Bumcrot D., Manoharan M., Koteliansky V., Sah D.W. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat. Chem. Biol. 2006, 2(12):711-719.
11. Lam J.K., Chow M.Y., Zhang Y., SW Leung siRNA versus miRNA as therapeutics for gene silencing. Mol. Ther.-Nucleic Acids 2015, 4.
12. DeVincenzo J., Cehelsky J.E., Alvarez R., Elbashir S., Harborth J., Toudjarska I., Nechev L., Murugaiah V., Van Vliet A., Vaishnaw A.K., Meyers R. Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antivir. Res. 2008, 77(3):225-231.
13. DeVincenzo J., Lambkin-Williams R., Wilkinson T., Cehelsky J., Nochur S., Walsh E., Meyers R., Gollob J., Vaishnaw A. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc. Natl. Acad. Sci. U. S. A. 2010, 107(19):8800-8805.
14. Zamora M.R., Budev M., Rolfe M., Gottlieb J., Humar A., Devincenzo J., Vaishnaw A., Cehelsky J., Albert G., Nochur S., Gollob J.A., Glanville A.R. RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. Am. J. Respir. Crit. Care Med. 2011, 183(4):531-538.
15. Chandra P.K., Kundu A.K., Hazari S., Chandra S., Bao L., Ooms T., Morris G.F., Wu T., Mandal T.K., Dash S. Inhibition of hepatitis C virus replication by intracellular delivery of multiple siRNAs by nanosomes. Mol. Ther. 2012, 20(9):1724-1736.
16. Geisbert T.W.H.L., Kagan E., Yu E.Z., Geisbert J.B., Daddario-DiCaprio K., Fritz E.A., Jahrling P.B., McClintock K., Phelps J.R., Lee A.C., Judge A., Jeffs L.B., MacLachlan I. Postexposure protection of guinea pigs against a lethal Ebola virus challenge is conferred by RNA interference. J. Infect. Dis. 2006, 193(12):1650-1657.
17. Yanagihara K., Tashiro M., Fukuda Y., Ohno H., Higashiyama Y., Miyazaki Y., Hirakata Y., Tomono K., Mizuta Y., Tsukamoto K., Kohno S. Effects of short interfering RNA against methicillin-resistant Staphylococcus aureus coagulase in vitro and in vivo. J. Antimicrob. Chemother. 2006, 57(1):122-126.
18. Lopez-Fraga M., Martinez T., Jimenez A. RNA interference technologies and therapeutics: from basic research to products. BioDrugs 2009, 23(5):305-332.
19. Agrawal N., Dasaradhi P.V.N., Mohmmed A., Malhotra P., Bhatnagar R.K., Mukherjee S.K. RNA interference: biology, mechanism, and applications. Microbiol. Mol. Biol. Rev. 2003, 67(4):657-685.
20. Heo I., Kim V.N. Regulating the regulators: posttranslational modifications of RNA silencing factors. Cell 2009, 139(1):28-31.
21. Rana T.M. Illuminating the silence: understanding the structure and function of small RNAs. Nat. Rev. Mol. Cell Biol. 2007, 8(1):23-36.
22. Sashital D.G., Doudna J.A. Structural insights into RNA interference. Curr. Opin. Struct. Biol. 2010, 20(1):90-97.
23. Deng Y., Wang C.C., Choy K.W., Du Q., Chen J., Wang Q., Li L., Chung T.K., Tang T. Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies. Gene 2014, 538(2):217-227.
24. Kim D.H., Rossi J.J. Strategies for silencing human disease using RNA interference. Nat. Rev. Genet. 2007, 8(3):173-184.
25. Pecot C.V., Calin G.A., Coleman R.L., Lopez-Berestein G., Sood A.K. RNA interference in the clinic: challenges and future directions. Nat. Rev. Cancer 2011, 11(1):59-67.
26. Bader A.G., Brown D., Winkler M. The promise of microRNA replacement therapy. Cancer Res. 2010, 70(18):7027-7030.
27. van Rooij E., Kauppinen S. Development of microRNA therapeutics is coming of age. EMBO Mol. Med. 2014, 6(7):851-864.
28. Coelho T., Adams D., Silva A., Lozeron P., Hawkins P.N., Mant T., Perez J., Chiesa J., Warrington S., Tranter E., Munisamy M., Falzone R., Harrop J., Cehelsky J., Bettencourt B.R., Geissler M., Butler J.S., Sehgal A., Meyers R.E., Chen Q., Borland T., Hutabarat R.M., Clausen V.A., Alvarez R., Fitzgerald K., Gamba-Vitalo C., Nochur S.V., Vaishnaw A.K., Sah D.W., Gollob J.A., Suhr O.B. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N. Engl. J. Med. 2013, 369(9):819-829.
29. Fitzgerald K., Frank-Kamenetsky M., Shulga-Morskaya S., Liebow A., Bettencourt B.R., Sutherland J.E., Hutabarat R.M., Clausen V.A., Karsten V., Cehelsky J., Nochur S.V., Kotelianski V., Horton J., Mant T., Chiesa J., Ritter J., Munisamy M., Vaishnaw A.K., Gollob J.A., Simon A. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. The Lancet 2014, 383(9911):60-68.
30. Leachman S.A., Hickerson R.P., Schwartz M.E., Bullough E.E., Hutcherson S.L., Boucher K.M., Hansen C.D., Eliason M.J., Srivatsa G.S., Kornbrust D.J., Smith F.J., McLean W.I., Milstone L.M., Kaspar R.L. First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Mol. Ther. 2010, 18(2):442-446.
31. Nguyen Q.D., Schachar R.A., Nduaka C.I., Sperling M., Basile A.S., Klamerus K.J., Chi-Burris K., Yan E., Paggiarino D.A., Rosenblatt I., Khan A., Aitchison R., Erlich S.S., Group P.F.S. Phase 1 dose-escalation study of a siRNA targeting the RTP801 gene in age-related macular degeneration patients. Eye 2012, 26(8):1099-1105.
32. Schultheis B., Strumberg D., Santel A., Vank C., Gebhardt F., Keil O., Lange C., Giese K., Kaufmann J., Khan M., Drevs J. First-in-human phase I study of the liposomal RNA interference therapeutic Atu027 in patients with advanced solid tumors. J. Clin. Oncol. 2014, 32(36):4141-4148.
33. Tabernero J., Shapiro G.I., LoRusso P.M., Cervantes A., Schwartz G.K., Weiss G.J., Paz-Ares L., Cho D.C., Infante J.R., Alsina M., Gounder M.M., Falzone R., Harrop J., White A.C., Toudjarska I., Bumcrot D., Meyers R.E., Hinkle G., Svrzikapa N., Hutabarat R.M., Clausen V.A., Cehelsky J., Nochur S.V., Gamba-Vitalo C., Vaishnaw A.K., Sah D.W., Gollob J.A., Burris H.A. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Can. Dis. 2013, 3(4):406-417.
34. Complete results of our ALN-RSV01 phase IIb study [updated 09/04/2012; cited 2016 27/01/2016]. Available from:. http://www.alnylam.com/capella/presentations/complete-results-of-our-aln-rsv01-phase-iib-study/.
35. Zumla A., Maeurer M., Host-Directed Therapies N, Chakaya J., Hoelscher M., Ntoumi F., Rustomjee R., Vilaplana C., Yeboah-Manu D., Rasolof V., Munderi P., Singh N., Aklillu E., Padayatchi N., Macete E., Kapata N., Mulenga M., Kibiki G., Mfinanga S., Nyirenda T., Maboko L., Garcia-Basteiro A., Rakotosamimanana N., Bates M., Mwaba P., Reither K., Gagneux S., Edwards S., Mfinanga E., Abdulla S., PJ Cardona, Russell J.B., Gant V., Noursadeghi M., Elkington P., Bonnet M., Menendez C., TN Dieye, Diarra B., Maiga A., Aseffa A., Parida S., Wejse C., Petersen E., Kaleebu P., Oliver M., Craig G., Corrah T., Tientcheu L., Antonio M., Rao M., McHugh T.D., Sheikh A., Ippolito G., Ramjee G., Kaufmann S.H., Churchyard G., Steyn A., Grobusch M., Sanne I., Martinson N., Madansein R., Wilkinson R.J., Mayosi B., Schito M., Wallis R.S. Towards host-directed therapies for tuberculosis. Nat. Rev. Drug Discov. 2015, 14(8):511-512.
36. Hawn T.R., Shah J.A., Kalman D. New tricks for old dogs: countering antibiotic resistance in tuberculosis with host-directed therapeutics. Immunol. Rev. 2015, 264(1):344-362.
37. Zumla A., Maeurer M. Host-directed therapies for tackling multi-drug resistant tuberculosis: learning from the Pasteur-Bechamp Debates. Clin. Infect. Dis. 2015, 61(9):1432-1438.
38. Bruns H., Stegelmann F., Fabri M., Dohner K., van Zandbergen G., Wagner M., Skinner M., Modlin R.L., Stenger S. Abelson tyrosine kinase controls phagosomal acidification required for killing of Mycobacterium tuberculosis in human macrophages. J. Immunol. 2012, 189(8):4069-4078.
39. Koo M.S., Manca C., Yang G., O'Brien P., Sung N., Tsenova L., Subbian S., Fallows D., Muller G., Ehrt S., Kaplan G. Phosphodiesterase 4 inhibition reduces innate immunity and improves isoniazid clearance of Mycobacterium tuberculosis in the lungs of infected mice. PloS ONE 2011, 6(2).
40. Ong C.W., Elkington P.T., Brilha S., Ugarte-Gil C., Tome-Esteban M.T., Tezera L.B., Pabisiak P.J., Moores R.C., Sathyamoorthy T., Patel V., Gilman R.H., Porter J.C., Friedland J.S. Neutrophil-derived MMP-8 drives AMPK-dependent matrix destruction in human pulmonary tuberculosis. PLoS Pathog. 2015, 11(5).
41. Subbian S., Tsenova L., O'Brien P., Yang G., Koo M.S., Peixoto B., Fallows D., Dartois V., Muller G., Kaplan G. Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungs. PLoS Pathog. 2011, 7(9).
42. Subbian S., Tsenova L., O'Brien P., Yang G., Koo M.S., Peixoto B., Fallows D., Zeldis J.B., Muller G., Kaplan G. Phosphodiesterase-4 inhibition combined with isoniazid treatment of rabbits with pulmonary tuberculosis reduces macrophage activation and lung pathology. Am. J. Pathol. 2011, 179(1):289-301.
43. Wallis R.S., Maeurer M., Mwaba P., Chakaya J., Rustomjee R., Migliori G.B., Marais B., Schito M., Churchyard G., Swaminathan S., Hoelscher M., Zumla A. Tuberculosis-advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers. Lancet Infect. Dis. 2016, 16(4):e34-e46.
44. Yogalingam G., Pendergast A.M. Abl kinases regulate autophagy by promoting the trafficking and function of lysosomal components. J. Biol. Chem. 2008, 283(51):35941-35953.
45. Barkan D., Liu Z., Sacchettini J.C., Glickman M.S. Mycolic acid cyclopropanation is essential for viability, drug resistance, and cell wall integrity of Mycobacterium tuberculosis. Chem. Biol. 2009, 16(5):499-509.
46. Jarlier V., Nikaido H. Mycobacterial cell wall: structure and role in natural resistance to antibiotics. FEMS Microbiol. Lett. 1994, 123(1-2):11-18.
47. Hawn T.R., Matheson A.I., Maley S.N., Vandal O. Host-directed therapeutics for tuberculosis: can we harness the host?. Microbiol. Mol. Biol. Rev. 2013, 77(4):608-627.
48. Rayasam G.V., Balganesh T.S. Exploring the potential of adjunct therapy in tuberculosis. Trends Pharmacol. Sci. 2015, 36(8):506-513.
49. Jayaswal S., Kamal M.A., Dua R., Gupta S., Majumdar T., Das G., Kumar D., Rao K.V. Identification of host-dependent survival factors for intracellular Mycobacterium tuberculosis through an siRNA screen. PLoS Pathog. 2010, 6(4).
50. Rosas-Taraco A.G., Higgins D.M., Sanchez-Campillo J., Lee E.J., Orme I.M., Gonzalez-Juarrero M. Local pulmonary immunotherapy with siRNA targeting TGFbeta1 enhances antimicrobial capacity in Mycobacterium tuberculosis infected mice. Tuberculosis 2011, 91(1):98-106.
51. Rosas-Taraco A.G., Higgins D.M., Sanchez-Campillo J., Lee E.J., Orme I.M., Gonzalez-Juarrero M. Intrapulmonary delivery of XCL1-targeting small interfering RNA in mice chronically infected with Mycobacterium tuberculosis. Am. J. Respir. Cell Mol. Biol. 2009, 41(2):136-145.
52. Dhiman R., Kathania M., Raje M., Majumdar S. Inhibition of bfl-1/A1 by siRNA inhibits mycobacterial growth in THP-1 cells by enhancing phagosomal acidification. Biochim. Biophys. Acta 2008, 1780(4):733-742.
53. Dhiman R., Raje M., Majumdar S. Differential expression of NF-kappaB in mycobacteria infected THP-1 affects apoptosis. Biochim. Biophys. Acta 2007, 1770(4):649-658.
54. Kathania M., Raje C.I., Raje M., Dutta R.K., Majumdar S. Bfl-1/A1 acts as a negative regulator of autophagy in mycobacteria infected macrophages. Int. J. Biochem. Cell Biol. 2011, 43(4):573-585.
55. Roberts E.A., Chua J., Kyei G.B., Deretic V. Higher order Rab programming in phagolysosome biogenesis. J. Cell Biol. 2006, 174(7):923-929.
56. Wang J., Yang K., Zhou L., Minhaowu, Y Wu, Zhu M., Lai X., Chen T., Feng L., M Li, Huang C., Zhong Q., Huang X. MicroRNA-155 promotes autophagy to eliminate intracellular mycobacteria by targeting Rheb. PLoS Pathog. 2013, 9(10).
57. Kim J.K., Yuk J.M., Kim S.Y., Kim T.S., Jin H.S., Yang C.S., Jo E.K. MicroRNA-125a inhibits autophagy activation and antimicrobial responses during mycobacterial infection. J. Immunol. 2015, 194(11):5355-5365.
58. Deretic V., Singh S., Master S., Harris J., Roberts E., Kyei G., Davis A., de Haro S., Naylor J., Lee H.H., Vergne I. Mycobacterium tuberculosis inhibition of phagolysosome biogenesis and autophagy as a host defence mechanism. Cell. Microbiol. 2006, 8(5):719-727.
59. Hestvik A.L., Hmama Z., Av-Gay Y. Mycobacterial manipulation of the host cell. FEMS Microbiol. Rev. 2005, 29(5):1041-1050.
60. Fabri M., Realegeno S.E., Jo E.K., Modlin R.L. Role of autophagy in the host response to microbial infection and potential for therapy. Curr. Opin. Immunol. 2011, 23(1):65-70.
61. Gutierrez M.G., Master S.S., Singh S.B., Taylor G.A., Colombo M.I., Deretic V. Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell 2004, 119(6):753-766.
62. Mizushima N., Ohsumi Y., Yoshimori T. Autophagosome formation in mammalian cells. Cell Struct. Funct. 2002, 27(6):421-429.
63. Levine B., Deretic V. Unveiling the roles of autophagy in innate and adaptive immunity. Nat. Rev. Immunol. 2007, 7(10):767-777.
64. Pfeffer S.R. Structural clues to Rab GTPase functional diversity. J. Biol. Chem. 2005, 280(16):15485-15488.
65. Via L.E., Deretic D., Ulmer R.J., Hibler N.S., Huber L.A., Deretic V. Arrest of mycobacterial phagosome maturation is caused by a block in vesicle fusion between stages controlled by rab5 and rab7. J. Biol. Chem. 1997, 272(20):13326-13331.
66. O'Connell R.M., Rao D.S., Baltimore D. microRNA regulation of inflammatory responses. Annu. Rev. Immunol. 2012, 30:295-312.
67. Kimmey J.M., Huynh J.P., Weiss L.A., Park S., Kambal A., Debnath J., Virgin H.W., Stallings C.L. Unique role for ATG5 in neutrophil-mediated immunopathology during M. tuberculosis infection. Nature 2015, 528(7583):565-569.
68. Behar S.M., Baehrecke E.H. Tuberculosis: autophagy is not the answer. Nature 2015, 528(7583):482-483.
69. Silva Miranda M., Breiman A., Allain S., Deknuydt F., Altare F. The tuberculous granuloma: an unsuccessful host defence mechanism providing a safety shelter for the bacteria?. Clin. Dev. Immunol. 2012, 2012:139127.
70. Davis J.M., Ramakrishnan L. The role of the granuloma in expansion and dissemination of early tuberculous infection. Cell 2009, 136(1):37-49.
71. Wallis R.S. Reconsidering adjuvant immunotherapy for tuberculosis. Clin. Infect. Dis. 2005, 41(2):201-208.
72. Ordway D., Higgins D.M., Sanchez-Campillo J., Spencer J.S., Henao-Tamayo M., Harton M., Orme I.M., Gonzalez Juarrero M. XCL1 (lymphotactin) chemokine produced by activated CD8 T cells during the chronic stage of infection with Mycobacterium tuberculosis negatively affects production of IFN-gamma by CD4 T cells and participates in granuloma stability. J. Leukoc. Biol. 2007, 82(5):1221-1229.
73. Bonecini-Almeida M.G., Ho J.L., Boechat N., Huard R.C., Chitale S., Doo H., Geng J., Rego L., Lazzarini L.C.O., Kritski A.L., Johnson W.D., McCaffrey T.A., Silva JRLe Down-modulation of lung immune responses by interleukin-10 and transforming growth factor (TGF-) and analysis of TGF- receptors I and II in active tuberculosis. Infection and. Immunity 2004, 72(5):2628-2634.
74. Kursar M., Koch M., Mittrucker H.W., Nouailles G., Bonhagen K., Kamradt T., Kaufmann S.H.E. Cutting edge: regulatory T cells prevent efficient clearance of Mycobacterium tuberculosis. J. Immunol. 2007, 178(5):2661-2665.
75. Turner J., Gonzalez-Juarrero M., Ellis D.L., Basaraba R.J., Kipnis A., Orme I.M., Cooper A.M. In vivo IL-10 production reactivates chronic pulmonary tuberculosis in C57BL/6 mice. J. Immunol. 2002, 169(11):6343-6351.
76. Rajaram M.V., Ni B., Dodd C.E., Schlesinger L.S. Macrophage immunoregulatory pathways in tuberculosis. Semin. Immunol. 2014, 26(6):471-485.
77. Redford P.S., Boonstra A., Read S., Pitt J., Graham C., Stavropoulos E., Bancroft G.J., O'Garra A. Enhanced protection to Mycobacterium tuberculosis infection in IL-10-deficient mice is accompanied by early and enhanced Th1 responses in the lung. Eur. J. Immunol. 2010, 40(8):2200-2210.
78. Redford P.S., Murray P.J., O'Garra A. The role of IL-10 in immune regulation during M. tuberculosis infection. Mucosal Immunol. 2011, 4(3):261-270.
79. Mayer-Barber K.D., Andrade B.B., Oland S.D., Amaral E.P., Barber D.L., Gonzales J., Derrick S.C., Shi R., Kumar N.P., Wei W., Yuan X., Zhang G., Cai Y., Babu S., Catalfamo M., Salazar A.M., Via L.E., Barry C.E., Sher A. Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature 2014, 511(7507):99-103.
80. Mayer-Barber K.D., Sher A. Cytokine and lipid mediator networks in tuberculosis. Immunol. Rev. 2015, 264(1):264-275.
81. Mayer-Barber K.D., Andrade B.B., Barber D.L., Hieny S., Feng C.G., Caspar P., Oland S., Gordon S., Sher A. Innate and adaptive interferons suppress IL-1alpha and IL-1beta production by distinct pulmonary myeloid subsets during Mycobacterium tuberculosis infection. Immunity 2011, 35(6):1023-1034.
82. Mayer-Barber K.D., Barber D.L., Shenderov K., White S.D., Wilson M.S., Cheever A., Kugler D., Hieny S., Caspar P., Nunez G., Schlueter D., Flavell R.A., Sutterwala F.S., Sher A. Caspase-1 independent IL-1beta production is critical for host resistance to mycobacterium tuberculosis and does not require TLR signaling in vivo. J. Immunol. 2010, 184(7):3326-3330.
83. Misra A., Hickey A.J., Rossi C., Borchard G., Terada H., Makino K., Fourie P.B., Colombo P. Inhaled drug therapy for treatment of tuberculosis. Tuberculosis 2011, 91(1):71-81.
84. Pham D.D., Fattal E., Tsapis N. Pulmonary drug delivery systems for tuberculosis treatment. Int. J. Pharm. 2015, 478(2):517-529.
85. Islam M.A., Park T.E., Singh B., Maharjan S., Firdous J., Cho M.H., Kang S.K., Yun C.H., Choi Y.J., Cho C.S. Major degradable polycations as carriers for DNA and siRNA. J. Control. Release 2014, 193:74-89.
86. Merkel O.M., Rubinstein I., Kissel T. siRNA delivery to the lung: what's new?. Adv. Drug Deliv. Rev. 2014, 75:112-128.
87. Merkel O.M., Zheng M., Debus H., Kissel T. Pulmonary gene delivery using polymeric nonviral vectors. Bioconjug. Chem. 2012, 23(1):3-20.
88. Scomparin A., Polyak D., Krivitsky A., Satchi-Fainaro R. Achieving successful delivery of oligonucleotides-from physico-chemical characterization to in vivo evaluation. Biotechnol. Adv. 2015, 33(6 Pt 3):1294-1309.
89. Williford J.M., Wu J., Ren Y., Archang M.M., Leong K.W., Mao H.Q. Recent advances in nanoparticle-mediated siRNA delivery. Annu. Rev. Biomed. Eng. 2014, 16:347-370.
90. Yin H., Kanasty R.L., Eltoukhy A.A., Vegas A.J., Dorkin J.R., Anderson D.G. Non-viral vectors for gene-based therapy. Nat. Rev. Genet. 2014, 15(8):541-555.
91. Healey G.D., Lockridge J.A., Zinnen S., Hopkin J.M., Richards I., Walker W. Development of pre-clinical models for evaluating the therapeutic potential of candidate siRNA targeting STAT6. PloS ONE 2014, 9(2).
92. Paulin R., Meloche J., Courboulin A., Lambert C., Haromy A., Courchesne A., Bonnet P., Provencher S., Michelakis E.D., Bonnet S. Targeting cell motility in pulmonary arterial hypertension. Eur. Respir. J. 2014, 43(2):531-544.
93. Conde J., Tian F., Hernandez Y., Bao C., Cui D., Janssen K.P., Ibarra M.R., Baptista P.V., Stoeger T., de la Fuente J.M. In vivo tumor targeting via nanoparticle-mediated therapeutic siRNA coupled to inflammatory response in lung cancer mouse models. Biomaterials 2013, 34(31):7744-7753.
94. Taratula O., Kuzmov A., Shah M., Garbuzenko O.B., Minko T. Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA. J. Control. Release 2013, 171(3):349-357.
95. Shim G., Choi H.W., Lee S., Choi J., Yu Y.H., Park D.E., Choi Y., Kim C.W., Oh Y.K. Enhanced intrapulmonary delivery of anticancer siRNA for lung cancer therapy using cationic ethylphosphocholine-based nanolipoplexes. Mol. Ther. 2013, 21(4):816-824.
96. Okuda T., Kito D., Oiwa A., Fukushima M., Hira D., Okamoto H. Gene silencing in a mouse lung metastasis model by an inhalable dry small interfering RNA powder prepared using the supercritical carbon dioxide technique. Biol. Pharm. Bull. 2013, 36(7):1183-1191.
97. De Backer L., Naessens T., De Koker S., Zagato E., Demeester J., Grooten J., De Smedt S.C., Raemdonck K. Hybrid pulmonary surfactant-coated nanogels mediate efficient in vivo delivery of siRNA to murine alveolar macrophages. J. Control. Release 2015, 217:53-63.
98. Oh B., Lee M. Combined delivery of HMGB-1 box a peptide and S1PLyase siRNA in animal models of acute lung injury. J. Control. Release 2014, 175:25-35.
99. Wu Y., Ma J., Woods P.S., Chesarino N.M., Liu C., Lee L.J., Nana-Sinkam S.P., Davis I.C. Selective targeting of alveolar type II respiratory epithelial cells by anti-surfactant protein-C antibody-conjugated lipoplexes. J. Control. Release 2015, 203:140-149.
100. Hillaireau H., Couvreur P. Nanocarriers' entry into the cell: relevance to drug delivery. Cell. Mol. Life Sci. 2009, 66(17):2873-2896.
101. Boussif O., Lezoualc'h F., Zanta M.A., Mergny M.D., Scherman D., Demeneix B., Behr J.P. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl. Acad. Sci. U. S. A. 1995, 92(16):7297-7301.
102. van de Wetering P., Moret E.E., Schuurmans-Nieuwenbroek N.M., van Steenbergen M.J., Hennink W.E. Structure-activity relationships of water-soluble cationic methacrylate/methacrylamide polymers for nonviral gene delivery. Bioconjug. Chem. 1999, 10(4):589-597.
103. Funhoff A.M., van Nostrum C.F., Koning G.A., Schuurmans-Nieuwenbroek N.M., Crommelin D.J., Hennink W.E. Endosomal escape of polymeric gene delivery complexes is not always enhanced by polymers buffering at low pH. Biomacromolecules 2004, 5(1):32-39.
104. Freeman E.C., Weiland L.M., Meng W.S. Modeling the proton sponge hypothesis: examining proton sponge effectiveness for enhancing intracellular gene delivery through multiscale modeling. J. Biomater. Sci. Polym. Ed. 2013, 24(4):398-416.
105. Liang W., Lam J.K. Endosomal escape pathways for non-viral nucleic acid delivery systems. Molecular Regulation of Endocytosis 2012, 421-467. InTech Open Access Publisher, (Chapter 17). B. Ceresa (Ed.).
106. Stegmann T. Membrane fusion mechanisms: the influenza hemagglutinin paradigm and its implications for intracellular fusion. Traffic 2000, 1(8):598-604.
107. Choi S.W., Lee S.H., Mok H., Park T.G. Multifunctional siRNA delivery system: polyelectrolyte complex micelles of six-arm PEG conjugate of siRNA and cell penetrating peptide with crosslinked fusogenic peptide. Biotechnol. Prog. 2010, 26(1):57-63.
108. Hatakeyama H., Ito E., Akita H., Oishi M., Nagasaki Y., Futaki S., Harashima H. A pH-sensitive fusogenic peptide facilitates endosomal escape and greatly enhances the gene silencing of siRNA-containing nanoparticles in vitro and in vivo. J. Control. Release 2009, 139(2):127-132.
109. Lam J.K., Liang W., Lan Y., Chaudhuri P., Chow M.Y., Witt K., Kudsiova L., Mason A.J. Effective endogenous gene silencing mediated by pH responsive peptides proceeds via multiple pathways. J. Control. Release 2012, 158(2):293-303.
110. El-Sayed A., Harashima H. Endocytosis of gene delivery vectors: from clathrin-dependent to lipid raft-mediated endocytosis. Mol. Ther. 2013, 21(6):1118-1130.
111. Sardo C., Farra R., Licciardi M., Dapas B., Scialabba C., Giammona G., Grassi M., Grassi G., Cavallaro G. Development of a simple, biocompatible and cost-effective inulin-diethylenetriamine based siRNA delivery system. Eur. J. Pharm. Sci. 2015, 75:60-71.
112. Lam J.K., Liang W., Chan H.K. Pulmonary delivery of therapeutic siRNA. Adv. Drug Deliv. Rev. 2012, 64(1):1-15.
113. Pilcer G., Amighi K. Formulation strategy and use of excipients in pulmonary drug delivery. Int. J. Pharm. 2010, 392(1-2):1-19.
114. Cone R.A. Barrier properties of mucus. Adv. Drug Deliv. Rev. 2009, 61(2):75-85.
115. Lai S.K., Wang Y.Y., Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv. Drug Deliv. Rev. 2009, 61(2):158-171.
116. Di Gioia S., Trapani A., Castellani S., Carbone A., Belgiovine G., Craparo E.F., Puglisi G., Cavallaro G., Trapani G., Conese M. Nanocomplexes for gene therapy of respiratory diseases: targeting and overcoming the mucus barrier. Pulm. Pharmacol. Ther. 2015, 34:8-24.
117. Beck-Broichsitter M., Merkel O.M., Kissel T. Controlled pulmonary drug and gene delivery using polymeric nano-carriers. J. Control. Release 2012, 161(2):214-224.
118. Dunnhaupt S., Kammona O., Waldner C., Kiparissides C., Bernkop-Schnurch A. Nano-carrier systems: strategies to overcome the mucus gel barrier. Eur. J. Pharm. Biopharm. 2015, 96:447-453.
119. Kim A.J., Boylan N.J., Suk J.S., Hwangbo M., Yu T., Schuster B.S., Cebotaru L., Lesniak W.G., Oh J.S., Adstamongkonkul P., Choi A.Y., Kannan R.M., Hanes J. Use of single-site-functionalized PEG dendrons to prepare gene vectors that penetrate human mucus barriers. Angew. Chem. 2013, 52(14):3985-3988.
120. Suk J.S., Kim A.J., Trehan K., Schneider C.S., Cebotaru L., Woodward O.M., Boylan N.J., Boyle M.P., Lai S.K., Guggino W.B., Hanes J. Lung gene therapy with highly compacted DNA nanoparticles that overcome the mucus barrier. J. Control. Release 2014, 178:8-17.
121. Hidalgo A., Cruz A., Perez-Gil J. Barrier or carrier? Pulmonary surfactant and drug delivery. Eur. J. Pharm. Biopharm. 2015, 95(Pt A):117-127.
122. Asai-Tajiri Y., Matsumoto K., Fukuyama S., Kan O.K., Nakano T., Tonai K., Ohno T., Azuma M., Inoue H., Nakanishi Y. Small interfering RNA against CD86 during allergen challenge blocks experimental allergic asthma. Respir. Res. 2014, 15:132.
123. Bitko V., Musiyenko A., Shulyayeva O., Barik S. Inhibition of respiratory viruses by nasally administered siRNA. Nat. Med. 2005, 11(1):50-55.
124. D'Alessandro-Gabazza C.N., Kobayashi T., Boveda-Ruiz D., Takagi T., Toda M., Gil-Bernabe P., Miyake Y., Yasukawa A., Matsuda Y., Suzuki N., Saito H., Yano Y., Fukuda A., Hasegawa T., Toyobuku H., Rennard S.I., Wagner P.D., Morser J., Takei Y., Taguchi O., Gabazza E.C. Development and preclinical efficacy of novel transforming growth factor-beta1 short interfering RNAs for pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 2012, 46(3):397-406.
125. Goh F.Y., Cook K.L., Upton N., Tao L., Lah L.C., Leung B.P., Wong W.S. Receptor-interacting protein 2 gene silencing attenuates allergic airway inflammation. J. Immunol. 2013, 191(5):2691-2699.
126. Khaitov M.R., Shilovskiy I.P., Nikonova A.A., Shershakova N.N., Kamyshnikov O.Y., Babakhin A.A., Zverev V.V., Johnston S.L., Khaitov R.M. Small interfering RNAs targeted to interleukin-4 and respiratory syncytial virus reduce airway inflammation in a mouse model of virus-induced asthma exacerbation. Hum. Gene Ther. 2014, 25(7):642-650.
127. Miyamoto S., Hattori N., Senoo T., Onari Y., Iwamoto H., Kanehara M., Ishikawa N., Fujitaka K., Haruta Y., Murai H., Yokoyama A., Kohno N. Intra-airway administration of small interfering RNA targeting plasminogen activator inhibitor-1 attenuates allergic asthma in mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 2011, 301(6):L908-L916.
128. Senoo T., Hattori N., Tanimoto T., Furonaka M., Ishikawa N., Fujitaka K., Haruta Y., Murai H., Yokoyama A., Kohno N. Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis. Thorax 2010, 65(4):334-340.
129. Bramsen J.B., Laursen M.B., Nielsen A.F., Hansen T.B., Bus C., Langkjaer N., Babu B.R., Hojland T., Abramov M., Van Aerschot A., Odadzic D., Smicius R., Haas J., Andree C., Barman J., Wenska M., Srivastava P., Zhou C., Honcharenko D., Hess S., Muller E., Bobkov G.V., Mikhailov S.N., Fava E., Meyer T.F., Chattopadhyaya J., Zerial M., Engels J.W., Herdewijn P., Wengel J., Kjems J. A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity. Nucleic Acids Res. 2009, 37(9):2867-2881.
130. Chernolovskaya E.L., Zenkova M.A. Chemical modification of siRNA. Curr. Opin. Mol. Ther. 2010, 12(2):158-167.
131. Laursen M.B., Pakula M.M., Gao S., Fluiter K., Mook O.R., Baas F., Langklaer N., Wengel S.L., Wengel J., Kjems J., Bramsen J.B. Utilization of unlocked nucleic acid (UNA) to enhance siRNA performance in vitro and in vivo. Mol. BioSyst. 2010, 6(5):862-870.
132. Odadzic D., Bramsen J.B., Smicius R., Bus C., Kjems J., Engels J.W. Synthesis of 2'-O-modified adenosine building blocks and application for RNA interference. Bioorg. Med. Chem. 2008, 16(1):518-529.
133. Veedu R.N., Wengel J. Locked nucleic acids: promising nucleic acid analogs for therapeutic applications. Chem. Biodivers. 2010, 7(3):536-542.
134. De Backer L., Braeckmans K., Stuart M.C., Demeester J., De Smedt S.C., Raemdonck K. Bio-inspired pulmonary surfactant-modified nanogels: a promising siRNA delivery system. J. Control. Release 2015, 206:177-186.
135. Chow M.Y., Lam J.K. Dry powder formulation of plasmid DNA and siRNA for inhalation. Curr. Pharm. Des. 2015, 21(27):3854-3866.
136. Buttini F., Colombo G., Kwok P.C.L., Wui W.T. Inhalation drug delivery: techniques and products. Aerodynamic Assessment for Inhalation Products: Fundamentals and Current Pharmacopoeial Methods 2013, 91-119. John Wiley & Sons, Ltd, (Ch. 6).
137. Dhand R. Nebulizers that use a vibrating mesh or plate with multiple apertures to generate aerosol. Respir. Care 2002, 47(12):1406-1416. (discussion 1416-1408).
138. Dalby R., Spallek M., Voshaar T. A review of the development of Respimat Soft Mist Inhaler. Int. J. Pharm. 2004, 283(1-2):1-9.
139. ® Soft Mist Inhaler and its clinical utility in respiratory disorders. Med. Device 2011, 4:145-155.
140. Feddah M.R., Brown K.F., Gipps E.M., Davies N.M. In-vitro characterisation of metered dose inhaler versus dry powder inhaler glucocorticoid products: influence of inspiratory flow rates. J. Pharm. Pharm. Sci. 2000, 3(3):318-324.
141. Berkenfeld K., Lamprecht A., McConville J.T. Devices for dry powder drug delivery to the lung. AAPS PharmSciTech 2015, 16(3):479-490.
142. Hoppentocht M., Hagedoorn P., Frijlink H.W., de Boer A.H. Technological and practical challenges of dry powder inhalers and formulations. Adv. Drug Deliv. Rev. 2014, 75:18-31.
143. Timsina M.P., Martin G.P., Marriott C., Ganderton D., Yianneskis M. Drug-delivery to the respiratory-tract using dry powder inhalers. Int. J. Pharm. 1994, 101(1-2):1-13.
144. Saint-Lorant G., Leterme P., Gayot A., Flament M.P. Influence of carrier on the performance of dry powder inhalers. Int. J. Pharm. 2007, 334(1-2):85-91.
145. Liang W., Chow M.Y., Lau P.N., Zhou Q.T., Kwok P.C., Leung G.P., Mason A.J., Chan H.K., Poon L.L., Lam J.K. Inhalable dry powder formulations of siRNA and pH-responsive peptides with antiviral activity against H1N1 influenza virus. Mol. Pharm. 2015, 12(3):910-921.
146. Riley T., Christopher D., Arp J., Casazza A., Colombani A., Cooper A., Dey M., Maas J., Mitchell J., Reiners M., Sigari N., Tougas T., Lyapustina S. Challenges with developing in vitro dissolution tests for orally inhaled products (OIPs). AAPS PharmSciTech 2012, 13(3):978-989.
147. Jensen D.K., Jensen L.B., Koocheki S., Bengtson L., Cun D., Nielsen H.M., Foged C. Design of an inhalable dry powder formulation of DOTAP-modified PLGA nanoparticles loaded with siRNA. J. Control. Release 2012, 157(1):141-148.
148. Jensen D.M., Cun D., Maltesen M.J., Frokjaer S., Nielsen H.M., Foged C. Spray drying of siRNA-containing PLGA nanoparticles intended for inhalation. J. Control. Release 2010, 142(1):138-145.
149. Liang W., Kwok P.C., Chow M.Y., Tang P., Mason A.J., Chan H.K., Lam J.K. Formulation of pH responsive peptides as inhalable dry powders for pulmonary delivery of nucleic acids. Eur. J. Pharm. Biopharm. 2014, 86(1):64-73.
150. du Toit L.C., Pillay V., Danckwerts M.P. Tuberculosis chemotherapy: current drug delivery approaches. Respir. Res. 2006, 7:118.
151. Lienhardt C., Cook S.V., Burgos M., Yorke-Edwards V., Rigouts L., Anyo G., Kim S.J., Jindani A., Enarson D.A., Nunn A.J. Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the study C randomized controlled trial. J. Am. Med. Assoc. 2011, 305(14):1415-1423.
152. Mitra A., Wu Y. Challenges and opportunities in achieving bioequivalence for fixed-dose combination products. AAPS J. 2012, 14(3):646-655.
153. Deng Z.J., Morton S.W., Ben-Akiva E., Dreaden E.C., Shopsowitz K.E., Hammond P.T. Layer-by-layer nanoparticles for systemic codelivery of an anticancer drug and siRNA for potential triple-negative breast cancer treatment. ACS Nano 2013, 7(11):9571-9584.
154. Jhaveri A.M., Torchilin V.P. Multifunctional polymeric micelles for delivery of drugs and siRNA. Front. Pharmacol. 2014, 5:77.
155. Kim C., Shah B.P., Subramaniam P., Lee K.B. Synergistic induction of apoptosis in brain cancer cells by targeted codelivery of siRNA and anticancer drugs. Mol. Pharm. 2011, 8(5):1955-1961.
156. Zhang Y., Schwerbrock N.M.J., Rogers A.B., Kim W.Y., Huang L. Codelivery of VEGF siRNA and gemcitabine monophosphate in a single nanoparticle formulation for effective treatment of NSCLC. Mol. Ther. 2013, 21(8):1559-1569.
157. Niu N.K., Yin J.J., Yang Y.X., Wang Z.L., Zhou Z.W., He Z.X., Chen X.W., Zhang X., Duan W., Yang T., Zhou S.F. Novel targeting of PEGylated liposomes for codelivery of TGF-beta1 siRNA and four antitubercular drugs to human macrophages for the treatment of mycobacterial infection: a quantitative proteomic study. Drug Des. Devel. Ther. 2015, 9:4441-4470.
158. Ahmad Z., Sharma S., Khuller G.K. Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. Int. J. Antimicrob. Agents 2005, 26(4):298-303.
159. Kaur R., Garg T., Malik B., Gupta U.D., Gupta P., Rath G., Goyal A.K. Development and characterization of spray-dried porous nanoaggregates for pulmonary delivery of anti-tubercular drugs. Drug Deliv. 2016, 23(3):882-887.
160. Pandey R., Khuller G.K. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis 2005, 85(4):227-234.